Kelly Gold

Ms. Gold is the Chief Financial Officer at CAMP4 Therapeutics. She is responsible for guiding and executing the company’s strategy for establishing innovative strategic and technology-based partnerships that allow CAMP4 to realize the full value of the regRNA Actuating Platform. In addition, Ms. Gold leads all corporate finance and accounting, investor relations and strategic financial planning activities at CAMP4.

Ms. Gold joined CAMP4 in 2017 and has held roles of increasing responsibility leading the Business Development and Finance functions, most recently as Chief Business Officer and SVP, Finance. Prior to joining CAMP4, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Prior to Biogen, Ms. Gold worked in the healthcare investment banking group at Deutsche Bank, advising on M&A, public and private equity offerings, leveraged finance transactions, and joint ventures to clients in the US, Latin America and Europe. She also worked in Deutsche Bank’s Latin American Investment Banking group in Mexico, executing dual-listed IPOs in the areas of financial services and oil and gas. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities operated by the CDC, the NIH, and the US Army.

Ms. Gold holds Bachelor’s degrees in Biochemistry and Mechanical Engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.